Senior Director
Kymera Therapeutics
Senior Director
Kymera Therapeutics
Biotech company engineering targeted protein degraders
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn.
The Senior Director, Outcomes, Value & Access will serve as Kymera’s strategic leader for health economics, real-world evidence (RWE), value communication, and payer-relevant medical strategy across the pipeline. Reporting to the VP of Medical Affairs, this role will shape and execute the company’s integrated outcomes and access strategy to support optimized patient access, informed clinical decision-making, and successful product commercialization. The ideal candidate is an experienced HEOR leader with deep immunology expertise (dermatology and/or respiratory strongly preferred), a proven track record preparing for and supporting launches, and significant experience engaging national and regional payer stakeholders.
Strategic Leadership & Vision
Health Economics & Outcomes Research (HEOR)
Real-World Evidence & Data Generation
Payer & External Stakeholder Engagement
Cross-Functional Collaboration & Enablement
Team Leadership & Development
Required
Preferred
Kymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment. All applicants will receive consideration for employment without regard to race, color, religion, creed, gender, national origin, age, disability, veteran status, pregnancy, sex, marital status, gender expression or identity, genetic information, sexual orientation, citizenship, or any other legally protected class.
Compensation
Biotech company engineering targeted protein degraders
Kymera Therapeutics develops therapies that remove disease-causing proteins using targeted protein degradation. The company’s Pegasus Platform helps identify which proteins to degrade and then uses molecules that recruit the cell’s waste machinery to break down those proteins, aiming to treat cancers and immune diseases. This approach can create multiple drug candidates across different diseases. Kymera’s products are advanced through collaborations, most notably with Sanofi, which supports research, licensing, and milestone-based payments. Unlike traditional drugs that inhibit a protein’s function, Kymera’s strategy eliminates the protein itself, potentially offering new treatment options for patients. The company’s goal is to deliver new, effective medicines by degrading harmful proteins, expanding options in the biopharmaceutical market and addressing unmet medical needs.
Explore more opportunities at Kymera Therapeutics